Femke M. de Man - Concepedia

Author

Femke M. de Man

Erasmus MC Cancer Institute ORCID

Also Known As

F. de Man, F.M. Man, F.M. de Man, Femke M de Man, Femke M. de Man, Femke de Man

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Erasmus MC Cancer Institute Erasmus MC Radboud University Nijmegen Catharina Ziekenhuis Leiden University Medical Center

About

Femke M. de Man is an author at Erasmus MC Cancer Institute specializing in medicine, pharmacotherapy, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	673
2	Pharmacology	3	3	270
3	Cancer Therapeutics	3	3	625
4	Health Sciences	1	1	403
5	Pharmacogenomics	1	1	48

Femke M. de Man

Publications

928

Citations

H-Index

Page 1

	Year	Citations
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man, The Lancet Oncology MedicineProspective Safety AnalysisCancer ManagementPharmacotherapyCancer Treatment	2018	403
Drug–drug interactions in patients treated for cancer: a prospective study on clinical interventions Roelof W. F. van Leeuwen, Frank G. A. Jansman, Patricia M. L. A. van den Bemt, Annals of Oncology Drug InteractionsMedicineCancer ManagementPharmacologyClinical Interventions	2015	135
A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man, European Journal of Cancer Upfront DpydMedicineMetronomic TherapyPharmacologyPharmacotherapy	2018	87
Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study Mirjam de With, Jonathan E. Knikman, Femke M. de Man, Clinical Pharmacology & Therapeutics	2022	54
UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients Emma C. Hulshof, Mirjam de With, Femke M. de Man, European Journal of Cancer Drug SafetyProspective SafetyPoor Metaboliser PatientsMedicineGenotype-guided Dosing	2022	48
Survival of Patients With Cancer With <i>DPYD</i> Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy—A Matched-Pair Analysis Jonathan E. Knikman, Tycho A. Wilting, Marta López‐Yurda, Journal of Clinical Oncology	2023	47
Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial Nadine L. de Boer, Alexandra R. M. Brandt‐Kerkhof, Eva V. E. Madsen, BMJ Open	2019	24
Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study Femke M. de Man, Koen G. A. M. Hussaarts, Mirjam de With, Clinical Pharmacology & Therapeutics	2018	21
Effects of Protein and Calorie Restriction on the Metabolism and Toxicity Profile of Irinotecan in Cancer Patients Femke M. de Man, Ruben A.G. van Eerden, Gerdien M. van Doorn, Clinical Pharmacology & Therapeutics	2020	21
Treatment Algorithm for Homozygous or Compound Heterozygous<i>DPYD</i>Variant Allele Carriers With Low-Dose Capecitabine Linda M. Henricks, Emma Kienhuis, Femke M. de Man, JCO Precision Oncology	2017	20

Page 1